Wednesday, June 20, 2007 - 18:30

Innate Pharma S.A. announced it has entered into a in-licensing agreement with Cancer Research Technology  (CRT) on novel TLR agent.

AttachmentSize
PR in english39.21 KB
CP en fran├žais40.23 KB